The text states, “Nrf2 activation leads to specific podocyte defects that significantly worsen the proteinuria injury. Keap1/Nrf2 targeted therapy may enhance glomerular damage in proteinuria nephropathy.” This directly contradicts the preceding and subsequent sentences that discuss the protective effects of Nrf2 activation (e.g., SFN and cinnamic aldehyde alleviating renal function deterioration).
Could the authors clarify this apparent contradiction? Is the pro-proteinuric effect specific to certain contexts (e.g., type of inducer, disease stage, or genetic background) that should be explicitly stated to avoid confusion?